Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 28, 2026

Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow?

View original at nasdaq.com
Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow? Key Points The company had a fine second quarter, and investors will be hoping for a repeat…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Starbucks attributed its solid second-quarter performance to the Back to Starbucks initiative

    60% confidence

  • Analysts collectively expect Starbucks to post just over $9.1 billion in revenue and $0.65 per share in net income for fiscal Q3 2026 — nearly 4% below the prior-year revenue figure but a 30% improvement in EPS year over year

    60% confidence

  • Starbucks is a mature business with a huge footprint that has little room to grow, and its stock is priced for hot growth with a forward P/E of almost 35 that profitability gains are unlikely to match; even a beat on Q3 earnings would not change this negative view

    60% confidence

  • Full-year 2026 comparable sales guidance raised to at least 5% growth (from more than 3% previously), and adjusted EPS guidance raised to $2.25-$2.45 (from $2.15-$2.40 previously)

    60% confidence

Data points we hold from this source

Starbucks Corporation · forward pe35 ratio
Starbucks Corporation · stock price23 percent_ytd_change
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow? — Source | Via News | ViaNews Market